Advair Generic: Mylan Takes Issue With US FDA's 'Major' Concerns

Dispute over analysis of inhaler device could delay launch of competitor to GSK's franchise until 2018; FDA's complete response letter to Mylan' deemed 'major.'

lung illustration

It doesn't appear there is going to be a quick fix to get Mylan NV's generic version of GlaxoSmithKline PLC's AdvairDiskus (fluticasone/salmeterol) to market. President Rajiv Malik told investors May 10 that the US FDA's complete response letter to its ANDA for Advair was deemed a "major CRL."

The company's first quarter sales and earnings release was the first chance investors have had to hear publicly from management...

More from Generics

More from Biosimilars & Generics